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• Limitations
• All case-control studies with relatively weak evidence strength
• All studies had small samples sizes (highest was 56) 
• Poor reproducibility: lack of description of participant selection and 
inclusion/exclusion criteria, or poor explanation of how samples were
prepared, or both 
• Selection bias/due to differing demographics between controls and 
cases and not controls not representing population correctly 
• Not controlling for confounding factors. 
• Studies differed in type of Raman spectroscopy, experiment set up, 
and instruments utilized
• Outcome measurements varied with only four studies measuring 
sensitivity and specificity and both blood serum studies calculating 
PPV and NPV
• 5/6 studies discovered Raman peaks and 5/6 showed peaks associated
with Amide I and Amide III at slightly different locations
• Maheedar et al: Amide I and Amide III present
• Viswanathan et al: 
• Amide I at 1648 cm-1 and 1658 cm-1
• Amide III at 1268 cm-1
• Owens et al: Amide III at 1265 cm-1
• Paraskevaidi et al:
• Amide I at 1657 cm-1
• Amide III at 1242 cm-1
• Ullah et al:
• Amide I at 1657 cm-1
• Amide III at 1277 cm-1
Discussion 
The Efficacy of Raman Spectroscopy in 
Diagnosing Ovarian Cancer
Disparities between study designs prevent adequate comparison of Raman 
spectroscopy in various sample types. Low validity of all six studies due to 
small sample sizes, lack of reproducibility, selection bias, and confounding 
factors, weaken the evidence that Raman spectroscopy can be used to 
diagnose ovarian cancer. The blood plasma and blood serum studies have 
improved designs and greater promise, but results are not statistically or 
clinically significant for any of the tissue/blood samples. 
Although these studies have weaknesses in validity and design, the stronger 
study designs and results of Raman spectroscopy in blood samples support 
its potential to detect ovarian cancer. Further research, with clinical trials 
consisting of larger, representative sample sizes, is needed to identify 
biomarker Raman peaks, standardize algorithms, and determine if Raman 
spectroscopy applied to blood samples can diagnose ovarian cancer. Raman 
spectroscopy must also be assessed for cost effectiveness, clinical 
application and diagnostic accuracy of early-stage ovarian cancer compared 
to current standards of CA-125 and transvaginal ultrasound.
Conclusion
Ovarian cancer affects 1 in 78 women and is the deadliest gynecologic
cancer. Early-stage disease is usually not diagnosed because women are
asymptomatic. Symptoms (back, abdominal, or pelvic pain; bloating or 
early satiety; constipation or diarrhea; or urinary symptoms) frequently 
appear in stages III and IV when mortality is high. Therefore, there is a need 
for non-invasive diagnostic tools that can identify ovarian cancer early. 
Current methods of screening in patients with symptoms include 
transvaginal ultrasound and obtaining cancer antigen 125 (CA125) levels in 
blood serum, but CA125 has low specificity and sensitivity. A better 
diagnostic test is needed more accurately diagnose ovarian cancer prior to 
surgery. This review assesses the efficacy of Raman spectroscopy in 
diagnosing ovarian cancer when applied to ovarian tissue, blood serum, and 
blood plasma of women with ovarian cancer.
Introduction
• Literature search completed with PubMed, EBSCO, and Cochrane 
library in May 2020
§ Search terms: “Raman spectroscopy” AND “ovarian cancer” AND 
“diagnosis”
§ Inclusion Criteria: human subjects, publication 2005-2020
§ Exclusion Criteria: literature reviews, other cancers, Raman spectroscopy 
of other samples, subjects already being treated for cancer, Raman 
spectroscopy applied to treatment, metastasis, recurrent cancer, or 
surgery
§ Six case control studies: two for ovarian tissue, two for blood plasma, 
two for blood serum. 
Methods





Maheedar et al 
(2007)
CC Total N: 15
Controls: 8 normal
Cases: 7 malignant
NIR-RS HR 320 spectrograph,
SDL-8530 laser: 785 nm, 100 
mW
Raman peaks; SN, SP 
of PCA, Mahalonobis, 
and Limit test
Viswanathan et al 
(2019)
CC Total N: 20
Controls: 5 healthy
Cases: 15 malignant
FTRS FT Raman BRUKER RFS 




Owens et al (2013) CC Total N: 8
Controls: 1 normal, 
3 benign
Cases: 4 malignant
CRS InVia Renishaw RS,
785 nm, 35 mW
Raman peaks, 
Classification rate
Paraskevaidi et al 
(2018)









Moisoi et al (2019) CC Total N: 52
Controls: 39 healthy





SERS InVia Renishaw RS, 532 nm, 
10 mW
SN, SP, PPV, NPV, 
Classification accuracy





Raman peaks; SN, SP, 
PPV, NPV of certain 
combinations of peaks 
and their p values
Table 1. Comparison of research designs for Raman  Spectroscopy of Ovarian Tissue vx. Blood  
Plasma vs. Blood Serum
Key: CC = Case-Control study; RS = Raman spectroscopy/spectrometer; NIR-RS = Near-infrared Raman spectroscopy; FTRS = Fourier transform 
Raman spectroscopy; SERS = Surface-enhanced Raman spectroscopy; CRS = Conventional Raman spectroscopy; PCA = principal component
analysis; CA-125 = Cancer antigen 125; SN = Sensitivity; SP = Specificity; PPV = Positive Predictive Value; NPV = Negative Predictive Value
Ovarian cancer has high mortality and is difficult to diagnose early utilizing 
CA125 levels and transvaginal ultrasound. Raman spectroscopy has been 
studied in other cancers and can be applied to tissues or blood samples.  
This review evaluates the ability of Raman spectroscopy to identify ovarian 
cancer in ovarian tissue, blood serum, and blood plasma samples from 
women diagnosed with the disease.  A literature search yielded six case 
control studies (two studies for each tissue type) that explore Raman 
spectroscopy applied to these samples. These experiments detected 
differences between the Raman spectra of ovarian cancer samples and 
normal tissues. However, the low validities and disparities between these 
studies and their results cannot support the hypothesis that Raman 
spectroscopy applied to  any of these three sample types is effective at 
diagnosing ovarian cancer. The variance of peaks in the spectra of diseased 
samples and normal samples does indicate that Raman spectroscopy has 
potential to be useful in identifying ovarian cancer, but further research with 
larger representative cohorts and standardized procedures and algorithms is
needed to determine its value as a diagnostic tool.
Abstract Results 
Ovarian Tissue Studies:
• Maheedhar et al (2008): Case control study of 15 participants measuring the sensitivity 
and specificity of Near infra-red Raman spectroscopy (NIR-RS) in identifying ovarian 
cancer in fresh ovarian tissues
• Viswanathan et al (2019): Case control study of 20 participants (5 healthy controls, 15 
cancer cases) to discover differences in Raman peaks between benign and malignant 
ovarian tissues using Fourier transform Raman spectroscopy( FTRS)
Blood Plasma Studies:
• Owens et al (2013): Case control study of eight participants assessing Raman peaks and 
ability to classify ovarian cancer using Raman spectroscopy of blood plasma.
• Paraskevaidi et al (2018): Case control study of 56 participants comparing sensitivity and 
specificity of Raman spectroscopy vs. Surface-enhanced Raman Spectroscopy (SERS) in 
recognizing ovarian cancer by analyzing blood plasma samples
Blood Serum Studies
• Moisoi et al (2019): Case control study that involves 52 participants and evaluates 
sensitivity, specificity, positive-predictive value (PPV), negative-predictive value, (NPV) 
and accuracy of SERS in detecting ovarian cancer with blood serum
• Ullah et al (2016): Case control study of 22 participants measuring Raman peaks, 
sensitivity, specificity, positive-predictive value, (PPV) and negative-predictive value 
(NPV) of peaks and their p-values in identifying ovarian cancer using blood serum
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